THE SEROTONIN SYNDROME - IMPLICATED DRUGS, PATHOPHYSIOLOGY AND MANAGEMENT

被引:142
作者
SPORER, KA
机构
[1] University of California, San Francisco, California
[2] Emergency Services, Room 1E21, San Francisco General Hospital, San Francisco, CA, 94110
关键词
D O I
10.2165/00002018-199513020-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The serotonin syndrome has increasingly been recognised in patients who have received combined serotonergic drugs. This syndrome is characterised by a constellation of symptoms (confusion, fever, shivering, diaphoresis, ataxia, hyperreflexia, myoclonus or diarrhoea) in the setting of the recent addition of a serotonergic agent. The most common drug combinations causing the serotonin syndrome are monoamine oxidase inhibitors (MAOIs) and serotonin selective reuptake inhibitors (SSRls), MAOIs and tricyclic antidepressants, MAOIs and tryptophan, and MAOIs and pethidine (meperidine). This syndrome is caused by excess serotonin (5-hydroxytryptamine; 5-HT) availability in the CNS at the 5-HT1A-receptor. There may also be some interaction with dopamine and 5-HT2-receptors. This syndrome probably has a low incidence, even among patients taking these drug combinations, and there is likely to be some other as yet unidentified inciting factor causing some patients to develop a full serotonin syndrome. Because fatalities and severe complications have accompanied the serotonin syndrome, the previously described drug combinations should be used cautiously or not at all. The serotonin syndrome is usually mild and, if managed with drug withdrawal and supportive therapy, generally improves within hours. Patients who develop hyperthermia should be treated aggressively with external cooling and paralysis. Serotonin (5-hydroxytryptamine; 5-HT) and its receptors have been the subject of intense research in recent years.([1]) These receptors have been demonstrated to have a role in multiple medical and psychiatric conditions, including depression, anxiety, migraine and emesis. A variety of agents that affect the serotonin system, either at individual receptor sites or by affecting the availability of serotonin, have been available for clinical use. Because of the greater use of agents affecting the serotonergic system, a syndrome of serotonin hyperstimulation has recently been reported more frequently.
引用
收藏
页码:94 / 104
页数:11
相关论文
共 126 条
[1]  
Hoyer D., Clarke D.E., Fozard J.R., Et al., International union of pharmacology classification or receptors for 5-hydroxytryptamine (serotonin), Pharmacol Rev, 46, 2, pp. 157-203, (1994)
[2]  
Sternbach H., The serotonin syndrome, Am J Psychiatry, 148, (1991)
[3]  
Kline S.S., Mauro L.S., Scala-Barnett D.M., Et al., Serotonin syndrome versus neuroleptic malignant syndrome a cause of death, Clin Pharm, 8, (1989)
[4]  
Beasley C.M., Masica D.N., Heiligenstein J.H., Et al., Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings, J Clin Psychopharmacol, 13, (1993)
[5]  
Neuvonen P.J., Pohjola-Sintonen S., Tacke U., Et al., Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses, Lancet, 342, (1993)
[6]  
Palmer H., Potentiation of pethidine, BMJ, 2, (1960)
[7]  
Reid N.C.R.W., Pethidine and phenelzine, BMJ, 1, (1962)
[8]  
Rivers N., Horner B., Possible lethal reaction between nardil and dextromethorphan, Can Med Assoc J, 103, (1970)
[9]  
Pope H.G., Jonas J.M., Hudson J.I., Et al., Toxic reaction to the combination of monoamine oxidase inhibitors and tryptophan, Am J Psychiatry, 142, (1985)
[10]  
Shaie S.J., Barriga C., The hazards of use of monoamine oxidase inhibitors in disturbed adolescents, Can Med Assoc J, 104, (1971)